Related Experiment Video

Updated: Apr 15, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K

Checkpoint inhibitors in treatment of metastatic mucosal melanoma

Bin Lian1, Jun Guo2

  • 1Department of Renal Cancer and Melanoma, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital & Institute, Beijing 100142, China.

Chinese Clinical Oncology
|April 6, 2015
PubMed

Insights

Mucosal melanoma (MM), a rare cancer, has a poor prognosis. This review evaluates current treatment trials for MM, highlighting limited knowledge despite advances in cutaneous melanoma therapies.

Area of Science:

  • Oncology
  • Dermatology
  • Medical Research

Background:

  • Mucosal melanoma (MM) is a rare cancer subtype with a notably poor prognosis.
  • Significant therapeutic advancements exist for cutaneous melanoma, but data for MM are limited.
  • Understanding treatment efficacy in MM is crucial due to its aggressive nature.

Purpose of the Study:

  • To systematically review and evaluate clinical trials investigating treatments for mucosal melanoma.
  • To summarize the current evidence base for MM therapies.
  • To identify knowledge gaps in MM treatment research.

Main Methods:

  • Comprehensive literature search of relevant clinical trials.
  • Systematic review and critical appraisal of selected studies.
  • Synthesis of findings regarding treatment outcomes and safety in MM patients.

Main Results:

  • Limited number of high-quality trials specifically for mucosal melanoma.
  • Variability in treatment responses and outcomes across different MM sites.
  • Identification of emerging therapeutic strategies and ongoing research areas.

Conclusions:

  • Current treatment options for MM are not well-established, necessitating further research.
  • Evidence-based treatment guidelines for MM are lacking.
  • Future research should focus on novel therapies and targeted treatments for mucosal melanoma.
Keywords:
Anti-programmed cell death 1checkpointimmunotherapyipilimumabmucosal melanoma (MM)

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

14.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
785